Stock Research Monitor: ARLZ, HTBX, and HEB
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com recalls the previous performance of Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), Heat Biologics Inc. (NASDAQ: HTBX), and Hemispherx Biopharma Inc. (NYSE AMER: HEB). The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors. Stock prices here can fluctuate dramatically, particularly in response to news developments concerning the success or failure of a particular drug.All you have to do is sign up today for this free limited time offer by clicking the link below.
On Thursday, shares in Hayward, California headquartered Anthera Pharmaceuticals Inc. recorded a trading volume of 2.37 million shares, which was above their three months average volume of 958,340 shares. The stock ended at $0.10, plummeting 12.34% from the last trading session. The Company's shares are trading below their 50-day moving average by 64.21%. Furthermore, shares of Anthera Pharma, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have a Relative Strength Index (RSI) of 23.62. Get the full research report on ANTH for free by clicking below at:
Mississauga, Canada headquartered Aralez Pharmaceuticals Inc.'s stock finished yesterday's session 3.43% lower at $0.35 with a total trading volume of 475,099 shares. The stock is trading below their 50-day moving average by 48.82%. Shares of the Company, which operates as a specialty pharmaceutical company in the US and Canada, have an RSI of 24.83. Get access to our top-rated research, including the free report on ARLZ at:
At the close of trading on Thursday, shares in Durham, North Carolina headquartered Heat Biologics Inc. saw a slight decline of 0.90%, ending the day at $2.20. The stock recorded a trading volume of 427,271 shares. The Company's shares have advanced 34.15% in the previous three months. The stock is trading 12.07% above its 50-day moving average. Moreover, shares of Heat Biologics, which focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the US, have an RSI of 39.09. Click here to subscribe for a free membership which welcomes you with our report on HTBX at:
Orlando, Florida headquartered Hemispherx Biopharma Inc.'s shares ended the day 1.73% lower at $0.31 with a total trading volume of 118,237 shares. The stock has gained 1.90% in the last month. The Company's shares are trading 3.06% below their 50-day moving average. Additionally, shares of Hemispherx Biopharma, which engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the US, have an RSI of 45.45.
On June 27th, 2018, Hemispherx Biopharma has announced the immediate expansion of its Treatment Protocol/Expanded Access Programs for ME/CFS in the United States, known as AMP-511, to new enrollees for the first time in more than a year.This opportunity to expand the scope of AMP-511 is based on the successful completion of the first phase of the Company's Ampligen manufacturing initiative producing sufficient quantities of Ampligen to support new enrollees in this FDA-approved program. Join our big investor community at Wall St. Equities today and get your free report on HEB at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFAÂ® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFAÂ® and Chartered Financial AnalystÂ® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities